activins has been researched along with Atrophy, Muscle in 19 studies
Activins: Activins are produced in the pituitary, gonads, and other tissues. By acting locally, they stimulate pituitary FSH secretion and have diverse effects on cell differentiation and embryonic development. Activins are glycoproteins that are hetero- or homodimers of INHIBIN-BETA SUBUNITS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Baicalin is a natural flavonoid that can reduce skeletal muscle atrophy in animal models of cancer cachexia by inhibiting NF-κB." | 3.83 | Baicalin supplementation reduces serum biomarkers of skeletal muscle wasting and may protect against lean body mass reduction in cancer patients: Results from a pilot open-label study. ( Bertona, M; Emanuele, E; Fiuza-Luces, C; Lucia, A; Morales, JS; Pareja-Galeano, H; Sanchis-Gomar, F, 2016) |
| "Cancer cachexia is characterized by a significant reduction in body weight resulting predominantly from loss of adipose tissue and skeletal muscle." | 2.48 | Cancer cachexia: mediators, signaling, and metabolic pathways. ( Fearon, KC; Glass, DJ; Guttridge, DC, 2012) |
| "Cachexia is frequent, deadly, and untreatable for patients with pancreatic ductal adenocarcinoma (PDAC)." | 1.72 | Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin. ( Koniaris, LG; Liu, S; Liu, Y; Narasimhan, A; Shahda, S; Silverman, LM; Wan, J; Young, AR; Zhong, X; Zimmers, TA, 2022) |
| "Compared to the healthy controls, COPD patients had upregulated Activin A expression." | 1.51 | Elevated serum Activin A in chronic obstructive pulmonary disease with skeletal muscle wasting. ( Chen, R; Ding, H; Fu, X; Gui, X; Ji, X; Zhou, G, 2019) |
| "Muscle wasting and cachexia have long been postulated to be key determinants of cancer-related death, but there has been no direct experimental evidence to substantiate this hypothesis." | 1.36 | Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. ( Boone, T; Chen, Q; Goldberg, AL; Han, HQ; Jiao, Q; Kwak, KS; Lacey, DL; Lu, J; Rosenfeld, R; Simonet, WS; Song, Y; Wang, JL; Zhou, X, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 6 (31.58) | 2.80 |
| Authors | Studies |
|---|---|
| Terker, AS | 1 |
| Ikizler, TA | 1 |
| Zhong, X | 2 |
| Narasimhan, A | 1 |
| Silverman, LM | 1 |
| Young, AR | 1 |
| Shahda, S | 2 |
| Liu, S | 2 |
| Wan, J | 1 |
| Liu, Y | 3 |
| Koniaris, LG | 2 |
| Zimmers, TA | 2 |
| Hulmi, JJ | 1 |
| Penna, F | 1 |
| Pöllänen, N | 1 |
| Nissinen, TA | 1 |
| Hentilä, J | 1 |
| Euro, L | 1 |
| Lautaoja, JH | 1 |
| Ballarò, R | 1 |
| Soliymani, R | 1 |
| Baumann, M | 1 |
| Ritvos, O | 2 |
| Pirinen, E | 1 |
| Lalowski, M | 1 |
| Cao, Z | 1 |
| Jose, I | 1 |
| Glab, J | 1 |
| Puthalakath, H | 1 |
| Osellame, LD | 1 |
| Hoogenraad, NJ | 1 |
| Lee, SJ | 1 |
| Lehar, A | 1 |
| Meir, JU | 1 |
| Koch, C | 1 |
| Morgan, A | 1 |
| Warren, LE | 1 |
| Rydzik, R | 1 |
| Youngstrom, DW | 1 |
| Chandok, H | 1 |
| George, J | 1 |
| Gogain, J | 1 |
| Michaud, M | 1 |
| Stoklasek, TA | 1 |
| Germain-Lee, EL | 1 |
| Solagna, F | 1 |
| Tezze, C | 1 |
| Lindenmeyer, MT | 1 |
| Lu, S | 1 |
| Wu, G | 1 |
| Zhao, Y | 1 |
| Mitchell, R | 1 |
| Meyer, C | 1 |
| Omairi, S | 1 |
| Kilic, T | 1 |
| Paolini, A | 1 |
| Pasternack, A | 1 |
| Matsakas, A | 1 |
| Kylies, D | 1 |
| Wiesch, JSZ | 1 |
| Turner, JE | 1 |
| Wanner, N | 1 |
| Nair, V | 1 |
| Eichinger, F | 1 |
| Menon, R | 1 |
| Martin, IV | 1 |
| Klinkhammer, BM | 1 |
| Hoxha, E | 1 |
| Cohen, CD | 1 |
| Tharaux, PL | 1 |
| Boor, P | 1 |
| Ostendorf, T | 1 |
| Kretzler, M | 1 |
| Sandri, M | 2 |
| Kretz, O | 1 |
| Puelles, VG | 1 |
| Patel, K | 1 |
| Huber, TB | 1 |
| Samant, SA | 1 |
| Kanwal, A | 1 |
| Pillai, VB | 1 |
| Bao, R | 1 |
| Gupta, MP | 1 |
| Marchetti, N | 1 |
| Zhou, G | 1 |
| Gui, X | 1 |
| Chen, R | 1 |
| Fu, X | 1 |
| Ji, X | 1 |
| Ding, H | 1 |
| Pons, M | 1 |
| Poirier, C | 1 |
| Jiang, Y | 1 |
| Liu, J | 1 |
| Sandusky, GE | 1 |
| Nakeeb, A | 1 |
| Schmidt, CM | 1 |
| House, MG | 1 |
| Ceppa, EP | 1 |
| Zyromski, NJ | 1 |
| Jiang, G | 1 |
| Couch, ME | 1 |
| Chen, JL | 1 |
| Walton, KL | 1 |
| Winbanks, CE | 1 |
| Murphy, KT | 1 |
| Thomson, RE | 1 |
| Makanji, Y | 1 |
| Qian, H | 1 |
| Lynch, GS | 1 |
| Harrison, CA | 1 |
| Gregorevic, P | 2 |
| Sartori, R | 1 |
| Hofmann, M | 1 |
| Halper, B | 1 |
| Oesen, S | 1 |
| Franzke, B | 1 |
| Stuparits, P | 1 |
| Tschan, H | 1 |
| Bachl, N | 1 |
| Strasser, EM | 1 |
| Quittan, M | 1 |
| Ploder, M | 1 |
| Wagner, KH | 1 |
| Wessner, B | 1 |
| Matsuyama, T | 1 |
| Ishikawa, T | 1 |
| Okayama, T | 1 |
| Oka, K | 1 |
| Adachi, S | 1 |
| Mizushima, K | 1 |
| Kimura, R | 1 |
| Okajima, M | 1 |
| Sakai, H | 1 |
| Sakamoto, N | 1 |
| Katada, K | 1 |
| Kamada, K | 1 |
| Uchiyama, K | 1 |
| Handa, O | 1 |
| Takagi, T | 1 |
| Kokura, S | 1 |
| Naito, Y | 1 |
| Itoh, Y | 1 |
| Ohsawa, Y | 1 |
| Takayama, K | 1 |
| Nishimatsu, S | 1 |
| Okada, T | 1 |
| Fujino, M | 1 |
| Fukai, Y | 1 |
| Murakami, T | 1 |
| Hagiwara, H | 1 |
| Itoh, F | 1 |
| Tsuchida, K | 2 |
| Hayashi, Y | 1 |
| Sunada, Y | 1 |
| Emanuele, E | 1 |
| Bertona, M | 1 |
| Pareja-Galeano, H | 1 |
| Fiuza-Luces, C | 1 |
| Morales, JS | 1 |
| Sanchis-Gomar, F | 1 |
| Lucia, A | 1 |
| Gilson, H | 1 |
| Schakman, O | 1 |
| Kalista, S | 1 |
| Lause, P | 1 |
| Thissen, JP | 1 |
| Zhou, X | 1 |
| Wang, JL | 1 |
| Lu, J | 1 |
| Song, Y | 1 |
| Kwak, KS | 1 |
| Jiao, Q | 1 |
| Rosenfeld, R | 1 |
| Chen, Q | 1 |
| Boone, T | 1 |
| Simonet, WS | 1 |
| Lacey, DL | 1 |
| Goldberg, AL | 1 |
| Han, HQ | 1 |
| Fearon, KC | 1 |
| Glass, DJ | 1 |
| Guttridge, DC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nephrotic Syndrome Study Network Under the Rare Diseases Clinical Research Network[NCT01209000] | 1,200 participants (Anticipated) | Observational | 2010-04-30 | Recruiting | |||
| The Investigation of the Mechanism of Cachexia Occurrence for Patients With Gastrointestinal Cancer[NCT04594863] | 100 participants (Anticipated) | Observational | 2020-11-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for activins and Atrophy, Muscle
| Article | Year |
|---|---|
TGFβ and BMP signaling in skeletal muscle: potential significance for muscle-related disease.
Topics: Activin Receptors; Activins; Animals; Autophagy; Bone Morphogenetic Protein Receptors; Bone Morphoge | 2014 |
Cancer cachexia: mediators, signaling, and metabolic pathways.
Topics: Activins; Cachexia; Humans; Interleukin-6; Lipolysis; Metabolic Networks and Pathways; Models, Biolo | 2012 |
17 other studies available for activins and Atrophy, Muscle
| Article | Year |
|---|---|
Untangling the fibers of sarcopenia: activin A in chronic kidney disease-associated muscle wasting.
Topics: Activins; Humans; Muscles; Muscular Atrophy; Renal Insufficiency, Chronic; Sarcopenia | 2022 |
Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.
Topics: Activins; Adenocarcinoma; Animals; Cachexia; Carcinoma, Pancreatic Ductal; Estradiol; Female; Follis | 2022 |
Muscle NAD
Topics: Activin Receptors; Activins; Acute-Phase Proteins; Animals; Cachexia; Cell Line, Tumor; Disease Mode | 2020 |
Generation of reporter cell lines for factors inducing muscle wasting in cancer cachexia.
Topics: Activins; Animals; Cachexia; Cell Line, Transformed; Genes, Reporter; Green Fluorescent Proteins; Hu | 2020 |
Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight.
Topics: Activin Receptors, Type II; Activins; Animals; Bone Resorption; Female; Male; Mice; Mice, Inbred C57 | 2020 |
Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs.
Topics: Activin Receptors, Type II; Activins; Animals; Cachexia; Disease Models, Animal; HEK293 Cells; Human | 2021 |
The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy.
Topics: Activin Receptors, Type II; Activins; Angiotensin II; Animals; Humans; Mice; Mice, Knockout; Muscle, | 2017 |
Anabolic Medications for Muscle Wasting in Chronic Obstructive Pulmonary Disease. Is the Evidence Getting Stronger?
Topics: Activin Receptors; Activins; Humans; Muscular Atrophy; Pulmonary Disease, Chronic Obstructive | 2019 |
Elevated serum Activin A in chronic obstructive pulmonary disease with skeletal muscle wasting.
Topics: Activins; Adult; Aged; Body Mass Index; Cachexia; Case-Control Studies; Female; Humans; Inhibin-beta | 2019 |
The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
Topics: Activin Receptors, Type II; Activins; Animals; Biomarkers; Body Weights and Measures; Cachexia; Carc | 2019 |
Elevated expression of activins promotes muscle wasting and cachexia.
Topics: Activin Receptors, Type II; Activins; Animals; Blotting, Western; Cachexia; Cell Line, Tumor; Cyclin | 2014 |
Serum concentrations of insulin-like growth factor-1, members of the TGF-beta superfamily and follistatin do not reflect different stages of dynapenia and sarcopenia in elderly women.
Topics: Activins; Adult; Age Factors; Aged; Aged, 80 and over; Austria; Biomarkers; Body Composition; Comorb | 2015 |
Tumor inoculation site affects the development of cancer cachexia and muscle wasting.
Topics: Activins; Animals; Cachexia; Cell Line, Tumor; Disease Models, Animal; Interleukin-6; Male; Mice; Mi | 2015 |
The Inhibitory Core of the Myostatin Prodomain: Its Interaction with Both Type I and II Membrane Receptors, and Potential to Treat Muscle Atrophy.
Topics: Activins; Animals; Caveolin 3; Cell Differentiation; Cell Line; Cell Membrane Structures; Chlorocebu | 2015 |
Baicalin supplementation reduces serum biomarkers of skeletal muscle wasting and may protect against lean body mass reduction in cancer patients: Results from a pilot open-label study.
Topics: Absorptiometry, Photon; Activins; Aged; Biomarkers; Body Weight; Cachexia; Endpoint Determination; F | 2016 |
Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin.
Topics: Activins; Animals; Cell Proliferation; Follistatin; Hypertrophy; Male; Mice; Mice, Knockout; Muscula | 2009 |
Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
Topics: Activin Receptors, Type II; Activins; Animals; Anorexia; Atrophy; Cachexia; Female; Humans; Inhibins | 2010 |